AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00792519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV support group
Description: group support
Study NCT00792519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: group cognitive behavioral treatment
Study NCT03276871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Dissection
Description: Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
Study NCT01803555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol SPIROMAX®
Description: BF Spiromax will be administered per dose and schedule specified in the arm.
Study NCT02063256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
Study NCT04201535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Protein arrays on plasma samples
Description: Protein arrays on plasma samples obtained from RA, OA patients and controls will be performed to identify a panel of acute phase proteins, cytokines and chemokines present at systemic levels and to highlight analogies and differences in the systemic protein profile.The synovial fluid will be used to identify through high-throughput MudPIT the proteins present in the synovial fluid of RA and OA patients.
Study NCT01786122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Physical activity
Description: Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
Study NCT01803555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYMBICORT® TURBOHALER®
Description: Symbicort Turbohaler will be administered per dose and schedule specified in the arm.
Study NCT01803555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYMBICORT placebo
Description: SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.
Study NCT01803555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPIROMAX Placebo
Description: SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
Study NCT03995498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Participants will engage in team sports exercise twice a day: from 9h:30 to 10h:30 and from 11h:00 to 12h:00.
Study NCT03995498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre
Description: Glucose levels will be measured by the FreeStyle Libre
Study NCT01786122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education program on healthy habits
Description: education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
Study NCT00296725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Description: Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. \*All increases only if tolerated.
Study NCT03995498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SenseWear Armband
Description: Energy expenditure during physical activity sessions will be measured with the SenseWear Armband.
Study NCT04093908 — intervention group
Intervention type: OTHER
Intervention: Prediction of motor outcome after STN DBS based on preoperative variables
Description: Generating individual probabilities for motor response based on preoperative variables
Study NCT03039361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine Assisted Psychotherapy
Description: Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
Study NCT01821612 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oxaliplatin
Description: IV
Study NCT01821612 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: irinotecan
Description: IV
Study NCT01821612 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: leucovorin
Description: IV
Study NCT01821612 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-fluorouracil
Description: IV
Study NCT01821612 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: capecitabine
Description: PO
Study NCT01821612 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation
Study NCT01821612 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Study NCT01821612 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine
Description: IV
Study NCT04526392 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Pubertal course questionnaire
Study NCT01477502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individual homeopathic treatment
Description: participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis
Study NCT01477502 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard treatment without homeopathy
Description: participants receive standard UTI prophylaxis
Study NCT06234774 — intervention group
Intervention type: PROCEDURE
Intervention: Robot-assisted laparoscopic surgery
Study NCT06234774 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional (non-robotic) laparoscopic surgery
Study NCT02772094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single arm, open-label
Description: Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.~Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ.
Study NCT01173913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc001 10mg capsules
Description: Bi-daily administration. One cycle will last 7 days
Study NCT01173913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc003 10mg tablets and ModraDoc004 10/50 mg
Description: The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
Study NCT01173913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006 10 mg tablet
Description: Bi-daily administration. One cycle will last 7 days
Study NCT03327714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and compassion
Study NCT01481870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib-sunitinib
Description: sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed
Study NCT01481870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib-sorafenib
Description: sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
Study NCT01435447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLu-Bu-Cy
Description: Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
Study NCT01347125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImCardia Device
Description: The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
Study NCT03762213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus GO VR HMD, application Happy Place (© Mimerse)
Description: The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
Study NCT03762213 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: iPad, application Happy Place (© Mimerse)
Description: The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
Study NCT03250052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (fimasartan or linagliptin) x 7days
Description: Part A: fimasartan, Part B: linagliptin
Study NCT03250052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (fimasartan and linagliptin) x 7days
Description: Part A \& Part B: Co-administration of fimasartan and linagliptin
Study NCT00736918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management, Usual clinical practice and Providing paper based information for suicide prevention
Study NCT00736918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Usual clinical practice and Providing paper based information for suicide prevention
Study NCT00933959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging Program
Description: Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
Study NCT00933959 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Treatment as usual
Study NCT05189314 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Surgical Resection of thyroid nodules
Study NCT05189314 — intervention group
Intervention type: DEVICE
Intervention: Radiofrequency Ablation
Description: Radiofrequency Ablation of thyroid nodules
Study NCT03623620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Delivery of Mindfulness-Based Cognitive Therapy
Description: 12-week program that emphasizes mindfulness and cognitive behavioral skills
Study NCT04385524 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Adjuvanted Hepatitis B Vaccine
Description: Adjuvanted Hepatitis B vaccine will be provided to healthcare workers previously vaccinated with the standard 3-dose series of Hepatitis B vaccine but who have failed to respond to two complete 3-dose series
Study NCT01212991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
Study NCT02099175 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients needing Elective Nodal Volume (ENI)
Description: 1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI:~HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed
Study NCT02099175 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients not needing ENI
Description: 1. Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed
Study NCT01212991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
Study NCT01523158 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Allergovit grass or birch
Description: subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
Study NCT04414904 — intervention group
Intervention type: OTHER
Intervention: Exposure: Covid-19 infection
Description: Previous history of COVID-19 infection.
Study NCT01926977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5mg
Description: Patient will receive intravitreal injection of Ranibizumab 0.5mg.
Study NCT01926977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2.0mg
Description: Patients will receive intravitreal injection of Aflibercept 2.0mg.
Study NCT01177696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic intervention
Description: A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
Study NCT02817282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hand hygiene implementation strategy
Description: Implementation strategy: Individual oriented activities. Education based on the different determinants influencing HCWs' behavior. Reminders for supporting the actual performance of HH; by distributing posters. Performance feedback for awareness. Goal setting will be encouraged and the feedback will be used to help HCWs evaluate their success and determine how they could best adapt their behavior in order to reach their goal. Organisational oriented activities. Products and facilities: The physical environment will be adapted by improving the availability of hand based hand rub. Team-oriented activities; The social environment will be adapted by training at a group and individual level, to improve social and descriptive norms. Positive role models will be stimulated through this training.
Study NCT03166865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical-cord mesenchymal stromal cells (UC-MSCs)
Description: Allogeneic UC-MSCs 1 x 10\~7 diluted on 5 mL of Platelet Rich Plasma
Study NCT03166865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyaluronic acid
Description: intra-articular injection of Hyaluronic Acid
Study NCT00702585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Org 36286 single-dose subcutaneous injection
Study NCT00702585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Org 36286 as a single-dose subcutaneous injection
Study NCT02222454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System
Description: KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
Study NCT02713191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure
Study NCT02713191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam bolus
Description: Midazolam 2 mg as slow intravenous bolus immediately prior to procedure
Study NCT02713191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline placebo
Description: 100 mL saline infusion over 10-15 minutes immediately prior to procedure
Study NCT06676761 — intervention group
Intervention type: PROCEDURE
Intervention: nipple sparing mastectomy without reconstruction
Description: nipple sparing mastectomy was conventionally performed with reconstruction. we aim to study the outcomes in the group of patients with Minimal scar mastectomy (MSM) who have nipple sparing mastectomy without reconstruction
Study NCT01048502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate (Tricor) tablets
Description: One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
Study NCT01048502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
Study NCT01048502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
Study NCT02594371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Study NCT02594371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV paclitaxel
Study NCT02208115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal composition - Low versus high GI.
Study NCT03808870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBM-BMX softgel capsules
Description: Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
Study NCT01969474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis capsules given once daily for a month
Study NCT01969474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00465049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRIMARY CLOSRE
Description: SUTURE
Study NCT01325233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
Study NCT01325233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml normal saline, tiw, 2 weeks
Study NCT02713191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue midazolam
Description: Rescue boluses of 0.5 mg midazolam, if needed during procedure
Study NCT02713191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue midazolam
Description: Rescue boluses of 0.5 mg midazolam, if needed during procedure
Study NCT06390852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06390852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06390852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT00465049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SECONDARY CLOSURE
Description: ALLOW TO HEAL SPONTANEOUSLY
Study NCT00465049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SPONTANEOUS HALING
Description: SECONDARY HEALING AFTER I\&D
Study NCT06390852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Description: Given PO
Study NCT06390852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02960659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide (6mg/ml, 3ml ) solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6mg, 1.2mg or 1.8mg.
Study NCT02960659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500mg oral tablet
Study NCT02960659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg oral tablet
Study NCT03947086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (TDCS)- Active
Description: A constant current stimulator (TCT Research Limited) will be used using electrodes of 5 × 5 cm2 embedded in saline (0.9 % NaCl) and application of 1.5 mA current for 20 minutes for 5 consecutive days. The cathode will be positioned in the right supra-orbital region, and while the anode will have the following provision in the left dorsolateral prefrontal cortex (F3).
Study NCT02713191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
Study NCT02713191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
Study NCT02336412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: Daily SMS medication reminder
Study NCT00705120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bone Marrow Cell Transplantation